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Key points
 Hyperekplexia or startle disease is a serious neurological condition affecting newborn children
and usually involves dysfunctional glycinergic neurotransmission.
 Glycine receptors (GlyRs) are major mediators of inhibition in the spinal cord and brainstem.
 A missense mutation, replacing asparagine (N) with lysine (K), at position 46 in the GlyR α1
subunit induced hyperekplexia following a reduction in the potency of the transmitter glycine;
this resulted from a rapid deactivation of the agonist current at mutant GlyRs.
 These effects of N46K were rescued by mutating a juxtaposed residue, N61 on binding Loop
D, suggesting these two asparagines may interact.
 Asparagine 46 is considered to be important for the structural stability of the subunit inter-
face and glycine binding site, and its mutation represents a new mechanism by which GlyR
dysfunction induces startle disease.
Abstract Dysfunctional glycinergic inhibitory transmission underlies the debilitating neuro-
logical condition, hyperekplexia, which is characterised by exaggerated startle reflexes, muscle
hypertonia and apnoea. Here we investigated theN46Kmissensemutation in the GlyR α1 subunit
gene found in the ethylnitrosourea (ENU) murine mutant, Nmf11, which causes reduced body
size, evoked tremor, seizures, muscle stiffness, and morbidity by postnatal day 21. Introducing
the N46K mutation into recombinant GlyR α1 homomeric receptors, expressed in HEK cells,
reduced the potencies of glycine, β-alanine and taurine by 9-, 6- and 3-fold respectively, and that
of the competitive antagonist strychnine by 15-fold. Replacing N46 with hydrophobic, charged
or polar residues revealed that the amide moiety of asparagine was crucial for GlyR activation.
Co-mutating N61, located on a neighbouring β loop to N46, rescued the wild-type phenotype
depending on the amino acid charge. Single-channel recording identified that burst length for the
N46K mutant was reduced and fast agonist application revealed faster glycine deactivation times
for the N46Kmutant compared with theWT receptor. Overall, these data are consistent with N46
ensuring correct alignment of the α1 subunit interface by interaction with juxtaposed residues to
preserve the structural integrity of the glycine binding site. This represents a new mechanism by
which GlyR dysfunction induces startle disease.
(Received 7 January 2016; accepted after revision 21 March 2016; first published online 29 March 2016)
Corresponding author T. G. Smart: Department of Neuroscience, Physiology and Pharmacology, University College
London, Gower Street, London WC1E 6BT, UK. Email: t.smart@ucl.ac.uk
Abbreviations DMEM, Dulbecco’s modified Eagle medium; DR, dose-ratio; ENU, ethylnitrosourea; GFP, green
fluorescent protein;GLRA1, GlyR α1 subunit gene;GLRB, GlyR β subunit gene; GluCl, glutamate-activated Cl˗ channel;
GlyR, glycine receptor; HEK-293, human embryonic kidney 293 cells; KB, equilibrium dissociation constant; Vpatch,
trans-patch potential; WT, wild type.
C© 2016 The Authors. The Journal of Physiology published by John Wiley & Sons Ltd on behalf of The Physiological Society DOI: 10.1113/JP272122
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution
and reproduction in any medium, provided the original work is properly cited.
3590 M. E. Wilkins and others J Physiol 594.13
Introduction
Hyperekplexia or startle disease is a serious neurological
condition affecting newborn children. It is characterised
by exaggerated startle reflexes following tactile and
acoustic stimuli, resulting in hypertonia and apnoea.
Although considered as a rare orphan disease (<200,000
affected individuals world-wide), this disorder can cause
developmental delay and sudden infant death (Davies
et al. 2010). The underlying cause of hyperekplexia
involves dysfunctional glycinergic transmission (Harvey
et al. 2008) and causative mutations are typically found
in the genes encoding GlyR α1 (GLRA1; Shiang et al.
1993, 1995; Chung et al. 2010) and β subunits (GLRB;
Rees et al. 2002), and the presynaptic glycine transporter,
GlyT2 (Rees et al. 2006).
Animal models of startle disease are crucial for under-
standing the complex genetics of hyperekplexia and
characteristic symptoms are exhibited by several mouse
mutants harbouring different mutations in the GlyR α1
subunit gene (GLRA1), including: spasmodic, oscillator,
cincinatti (Graham et al. 2006; Schaefer et al. 2013) and
Nmf11 (Traka et al. 2006). In the spasmodic mouse, a
missense mutation (A52S) in the extracellular domain of
GlyR α1, caused a relatively mild phenotype, with homo-
zygous mice appearing normal at rest but developing an
exaggerated startle response to acoustic or tactile stimuli
at around 2 weeks of age (Lane et al. 1987). Although
located outside the ligand-binding domain, A52S reduced
the sensitivity to glycine and the co-operativity of binding
with increased ligand occupancy (Ryan et al. 1994; Plested
et al. 2007). By contrast, oscillator homozygotes and
the spontaneous mutant cincinatti exhibit a more severe
lethal phenotype due to a microdeletion in Glra1 exon
8 or duplication of Glra1 exon 5, respectively, causing
a complete loss of functional GlyRs (Kling et al. 1997;
Graham et al. 2006). The ENU-induced mutant, Nmf11,
also produces a lethal phenotype following a missense
mutation (N46K) in the extracellular domain of GlyR α1
(Traka et al. 2006). The lethality of the Nmf11 mutation
(N46K) is, however, puzzling, because neither α1 sub-
unit protein levels nor the somatodendritic distribution
of GlyRs are affected, discounting trafficking or clustering
deficits (Traka et al. 2006).
Although N46 lies in proximity to the glycine binding
site, it does not form part of an identified binding
loop or transduction pathway. However, from homology
modelling and from glycine receptor structures at atomic
level resolution, N46 is located at the subunit–subunit
interface, opposing binding loop A (Vafa et al. 1999; Du
et al. 2015; Huang et al. 2015) and sited between loops
D and F, which are involved in agonist binding (Miller
& Smart, 2010). We found that the GlyR α1 sensitivity
for glycine was substantially reduced by N46K due to
an increased rate of glycine deactivation of the mutant
receptor. Our data identify an approximate threshold for
the reduction in glycine potency that results in lethality of
GlyRmutantmice, in addition touncovering a role forN46
in GlyR activation/ deactivation and a newmechanism for
hyperekplexia.
Methods
HEK cell transfection and mutagenesis
Human embryonic kidney (HEK293) cells were grown in
DMEMsupplementedwith 10%v/v fetal calf serum, 2mM
L-glutamine, 100 u ml−1 penicillin-G and 100 μg ml−1
streptomycin in a 5 % CO2–air atmosphere at 37 °C.
Cells were harvested and plated onto poly-L-lysine-coated
22 mm coverslips (VWR, Leuven, Belgium) and trans-
fected with recombinant murine GlyRs 1–3 h later using
a modified calcium phosphate precipitation method. For
homomeric GlyRα1, the cells were co-transfected with
1.5μgpcDNA3-wild-typeormutant rGlyRα1with1.5μg
pRK5-eGFP for identifying transfected cells (1:1 ratio).
For heteromeric αβ GlyRs, cells were co-transfected with
pcDNA3-rGlyR β subunit (α:β:GFP in a 1:10:1 ratio;
4 μg total DNA). Mutations were made using the
StratageneQuikchangemethod. To increase efficiency, the
rGlyRα1N61mutationPCRproductswere subject toDpnI
digestion (NEB, Hitchin, UK), and methylation (NEB)
prior to ligation. All mutated cDNAs were completely
sequenced (SourceBiosciences,Nottingham,UK) to check
the inclusion and position of the mutations.
DNA solutions were incubated with 20 μl of 340 mM
CaCl2 and 24 μl of double-strength Hanks’ balanced salt
solution (280 mM NaCl; 2.8 mM Na2HPO4; 50 mM Hepes;
pH 7.2) for 5–10 min prior to drop-wise addition to the
plated cells. After 16–48hpost transfection, cellswere used
for electrophysiological recording.
Whole-cell recording
Glycine-activated currents were recorded from single
transfected HEK293 cells using whole-cell patch clamp
recording with an Axopatch 200B amplifier. Patch electro-
des (resistances of 3–4M)were filled an internal solution
containing (mM): 120 KCl, 1 MgCl2, 1 CaCl2, 10 Hepes,
11 EGTA, 30 KOH, 2 ATP and 0.5 GTP, pH 7.11 with
1 M NaOH. The cells were continuously perfused with
a physiological salt solution containing (mM): 140 NaCl,
4.7 KCl, 1.2 MgCl2, 2.5 CaCl2, 5 Hepes, and 11 D-glucose,
pH 7.4.
HEK293 cells were voltage-clamped at −10 mV
and visualised using a Nikon Diaphot 300 micro-
scope configured for differential interference contrast and
epifluorescence. A Y-tube enabled the rapid application of
drugs to the HEK cells. Data were recorded directly to a
Dell Pentium 4 computer via aDigidata 1320A (Molecular
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Devices, Sunnyvale, CA, USA) sampling at 15 kHz and
filtered at 5 kHz (6th order Bessel). The currents were
normalised to themaximumresponse amplitude activated
by a saturating glycine concentration applied to each
cell. Maximal responses, half-maximal concentrations
(EC50) and Hill coefficients were determined from
concentration–response data fitted using theHill equation
with non-linear least squares routines (Origin 6.0) as pre-
viously described (Miller et al. 2005a). The biphasic curve
data that resulted from the modulation of GlyR function
by Zn2+ was fitted using a modified Hill equation as pre-
viously described (Miller et al. 2004). Any change that
exceeded 10%of themembrane conductance and/or series
resistance resulted in cessation of the recording. For all
recordings, series resistance compensation to 80% was
achieved.
Schild analysis
Glycine concentration–response curves were constructed
in the absence and presence of three different
concentrations of strychnine. From the parallel curve
shifts, the glycine concentrations that produced 50%of the
maximum response in the absence (d) and presence (ds)
of strychnine weremeasured. The dose-ratios (DR= ds/d)
were calculated and used in the Schild plot of log
(DR − 1) against the log antagonist concentration ([B])
(Arunlakshana & Schild, 1959). Initially, the unweighted
data were fitted with a power function of the form:
DR − 1 = c[B]n,
where c is a constant and n is the slope of the plot. In
all analyses, the slopes of the lines were not significantly
different from unity (P > 0.05, two-tailed t test) as
expected for an antagonist that acts in a purely competitive
manner. The data were then re-fitted with the Schild
equation using a constrained slope of 1:
(DR − 1) = [B] /KB.
The intercept of the line when (DR − 1) = 1 enabled
the equilibrium constant for strychnine (KB) to be
determined. The upper and lower 95% confidence limits
of the regression line were also calculated.
Single-channel recording analysis
Single glycine-activated channel currents were recorded
from cell-attached patches from transfected HEK293
cells expressing WT and N46K homomeric α1 sub-
unit GlyRs. Patches were held at +100 mV and the
recorded currents were filtered at 5 kHz and sampled
at 30 kHz. Thick-walled borosilicate patch electrodes
(8–10 M) were filled with external physiological salt
solution containing (mM): 102.7, NaCl; 20, sodium
gluconate; 4.7, KCl; 2, CaCl2.2H2O; 1.2, MgCl2.6H2O;
10, Hepes; 14, glucose; 15, sucrose; 20, TEACl; pH 7.4;
320 mosmol l–1. For single-channel experiments with
WT GlyRs, the pipette solution incorporated an EC60
concentration of either glycine (0.05 mM) or taurine
(0.4 mM). For the N46K experiments, the pipette solution
was supplemented with equivalent EC60 concentrations of
either glycine (0.5 mM) or taurine (0.9 mM).
Stored, pre-filtered single-channel recordswere assessed
for simultaneous opening of multiple channels, but
this usually formed less than 5% of the total opening
events. These multiple openings were not used in the
analyses.Currentswere analysedusing Strathclyde electro-
physiology software (John Dempster, WinEDR ver 3.5.2).
Open and shut durations were measured using a 50%
threshold cursor applied to the main single-channel
current amplitude in each patch. As with all threshold
cursor methods for detecting single-channel state trans-
itions, very brief shuttings can be missed, increasing
the duration of adjacent open periods (Mortensen &
Smart, 2007), but with the large glycine single-channel
currents and their lack of sub-conductance states, this
was considered not to be a confounding problem.
Dwell time frequency distributions were constructed from
the detected individual open and shut durations. The
minimum duration of resolvable events was set to 30 μs
before fitting the dwell-time histograms with one or more
exponentials, defined by the equation below.
y(t) =
n∑
i=1
(
Ai
τi
)
exp(−t/τ) ,
where Ai represents the area of the ith component
to the distribution and τi represents the respective
time constant. Using a Levenberg-Marquardt non-linear
least-squares routine, the areas of the individual
exponential components, their relative time constants and
standard errors of these parameters were determined.
Clusters of channel activations were recognised by their
separation from each other with long desensitised periods.
Where this was not easily recognisable, we determined
a critical shut time (τcrit; Colquhoun & Sakmann,
1985). This was determined between the longer shut
time constants, τC2 and τC3, as described previously
(Colquhoun & Sakmann, 1985; Mortensen et al. 2004;
Mortensen & Smart, 2007). The number of trans-
itions recorded per patch were 6000—12,000. Statistical
significance was determined using an unpaired t test.
Macropatch recordings
Outside-out macropatches were voltage-clamped at
−20 mV and recorded currents filtered at 5 kHz and
sampled at 30 kHz. Thick-walled borosilicate patch
electrodes (5–10 M) contained the same internal
C© 2016 The Authors. The Journal of Physiology published by John Wiley & Sons Ltd on behalf of The Physiological Society
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solution used forwhole-cell recording. Cells were perfused
with physiological salt solution. A theta glass electrode,
pulled and cut with a diamond knife to a tip diameter
of 50–100 μm, was used to apply adjacent solution
streams for rapid exchange over the macropatch. Solution
exchange was achieved by activating a piezoelectric
transducer (Burleigh Instruments, Dortmund, Germany)
that translated the solution interface for a specified
time (2–200 ms). Open tip potentials were measured
at the conclusion of each patch to confirm exchange
rates (usually 150–300 μs). Application durations were
programmed for multiple pulses, then averaged to reduce
signal/noise ratios. Rise and deactivation times were
calculated between 10 and 90 % of the peak current
amplitude and reported as means ± SEM.
Homology modelling
The sequence alignments between GlyRα1 and the C.
elegans glutamate-activated Cl˗ channel (GluCl; Hibbs
& Gouaux, 2011) were constructed using ClustalW
(Thompson et al. 1994). The mature GlyR α1 sub-
unit was then modelled as a subunit interface dimer,
based on the crystal structure template for GluCl (PDB
3RHW) in complex with Fab and ivermectin, using
Modeller 9 ver. 7 (Sali & Blundell, 1993). The models with
the lowest Discrete Optimised Protein Energy (DOPE)
score were used and optimal side-chain configurations
were determined with SCWRL4 (Krivov et al. 2009). All
structural images were rendered in PyMOL Molecular
Graphics System (DeLano, Palo Alto, CA, USA; Pettersen
et al. 2004). Subsequently, with the cryo-electron micro-
scopic and X-ray crystallographic structures for zebrafish
α1 (Du et al. 2015) and human α3 GlyRs (Huang et al.
2015) identified, wewere able to refine our rGlyRα1model
using Modeller and PyMOL.
Kinetic modelling
Channelab (ver 2, Synaptosoft, GA, USA) was used to
generate the simulated whole-cell currents to glycine
on WT and N46K GlyRα1. The binding/unbinding rate
constants, and gating and preactviation constants, are
generally in accord with values previously determined
and published for GlyRs (Burzomato et al. 2004). The
desensitisation rates were empirically chosen to account
for the profile of the current recordings forWT and N46K
GlyRα1.
Statistics
Statistical significance was determined using Graphpad
Instat ver 3.06. Significant differences between groups of
data were measured using an unpaired t test using raw or
mean ± SEM data with n numbers stated in the text.
Results
N46K mutation reduces glycine potency
Here we compared the glycine sensitivities of both homo-
meric and heteromeric GlyRs incorporating the N46K
mutation in the α1 subunit with wild-type receptors and
the phenotypically less severe A52S mutation. Asparagine
46 is located in the extracellular domain, within the
β1 loop (Brejc et al. 2002; Du et al. 2015) just before
binding loop D of the GlyRα1 subunit (Fig. 1A).
Glycine-activated currents for homomeric N46K GlyRα1
were comparable with those for WT receptors (Fig. 1B)
with saturating concentrations of glycine (1 and 10 mM,
respectively) revealing only a small, but insignificant,
decrease in maximal current: 3245 ± 570 pA (WT;
n = 14) and 2209 ± 367 pA (N46K, n = 19, P > 0.05).
However, the glycine concentration–response curves
revealed differences in potency (Fig. 1C). For GlyRα1
the glycine EC50 was 41 ± 3 μM (n = 20); whereas for
GlyRα1N46K, glycine was 9-fold less sensitive with an EC50
of 372 ± 4 μM (n = 19).
Heteromeric receptors (GlyRα1β) for WT and
N46K exhibited comparable maximal glycine currents:
4840 ± 1019 pA (α1β, n = 6) and 4871 ± 460 pA
(α1N46Kβ, n= 8,P> 0.05)with a smaller 5-fold separation
in receptor sensitivity to glycine; the respective EC50s
being: 64 ± 6 μM (α1β; n = 6) and 318 ± 79 μM
(α1N46Kβ;n= 8; Fig. 1C). This suggested that theβ subunit
partly rescued the N46K hyperekplexia mutation effect
on glycine current, which might be expected given that
the β subunit is replacing mutant α subunits in the α1β
heteromeric GlyR. Co-assembly of α and β subunits was
confirmed by a reduced inhibition of the EC50 glycine
steady-state response by picrotoxin (20 μM) (see below;
Fig. 5F). Thus, homomericα1GlyRs are themost sensitive
to the N46K mutation.
As the phenotype for the Nmf11 mouse was more
severe (Traka et al. 2006) than that for spasmodic, which
harbours the A52S mutation (Lane et al. 1987; Ryan et al.
1994), we compared the relative potencies of glycine.
Glycine was more potent at α1A52S than α1N46K GlyRs,
reflected by the relative displacements of the glycine
concentration–response curves and the resulting glycine
EC50s (Fig. 1D).
GlyR sensitivities to partial agonists and strychnine
are affected by N46K
To examine if the predominant effect of N46K is
centred on the agonist binding site, the partial agonists
β-alanine, taurine and GABA were studied. For a full
agonist, a reduction in efficacy can manifest as just a
rightward displacement of the concentration–response
curve; whereas a changed efficacy is often more evident
with a partial agonist, revealed by an additional lower
C© 2016 The Authors. The Journal of Physiology published by John Wiley & Sons Ltd on behalf of The Physiological Society
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maximum response. β-Alanine was 6-fold less potent
at N46K receptors compared to WT – without any
change in the relative maximum response (Fig. 2A).
For the less potent partial agonists taurine and GABA,
the curve displacements were less apparent: only 3-fold
for taurine (EC50: WT, 0.34 ± 0.03 mM; N46K
0.98 ± 0.23 mM; n = 7–8) and 1.5-fold for GABA (EC50:
WT, 21.27± 2.23 mM; N46K, 34.86± 6mM; n= 5), again
without any significant changes to the relative maximum
responses (Fig. 2B). This supported the hypothesis that
N46K reduced ligand binding rather than agonist efficacy.
To further probe the role of N46K on the
orthosteric binding site, inhibition by the competitive
antagonist strychnine was examined (Ruiz-Gomez et al.
1990; Vandenberg et al. 1992). The sensitivities of
α1WT and α1N46K GlyRs to inhibition by strychnine
were assessed with glycine EC50 responses. Strychnine
concentration–inhibition curves indicated that the
potency of the antagonist was reduced 15-fold by N46K
(Fig. 2C), which is similar to the shift observed in glycine
potency by N46K.
To determine if the reduced strychnine inhibition was
due to a reduction in the binding affinity, we performed
a Schild analysis. Shifts in the glycine concentration–
response curve following exposure to 0.1, 0.3 and 1 μM
strychnine for wild-type, and 1, 3 and 10 μM for N46K
were constructed. N46K caused an approximate 4.5-fold
increase in the strychnine equilibrium dissociation
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Figure 1. N46K GlyR is less sensitive to glycine
A, primary sequence alignment comparing rat (r) and zebrafish (zf) GlyR α1 and β subunits to other pentameric
ligand-gated ion channel (pLGIC) family members: mouse (m) GABAAR α2 and C. elegans GluCl. The amino acid
numbering refers to the mature rGlyR α1. The red highlighted residues indicate those mutated in this study. The
black bold residues form β sheets, whilst those residues that form ligand binding loops and interspersed β loops
are boxed. B, sample whole-cell currents activated by 0.01, 0.03, 0.1, 0.3 and 1 mM glycine for WT α1 (upper
left) and 0.03, 0.1, 0.3, 1, 3 and 10 mM glycine for α1N46K (lower left). Right panels show EC20 and maximal
glycine-activated currents for HEK cells expressing heteromeric WT and N46K GlyRs. Bars indicate the durations
of glycine application. C, concentration–response curves normalised to the maximal glycine-activated response
for homomeric α1 and heteromeric α1β wild-type (WT) and N46K GlyRs. In all figures, the symbols represent
means ± SEM. D, comparing concentration–response curves for glycine at WT, N46K and A52S mutant GlyRα1.
The A52S homomeric and heteromeric GlyR EC50s of 101 ± 10 μM (n = 9) and 118 ± 4 μM (n = 6) are significantly
lower than that for the N46K GlyR (P < 0.05).
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constant (KB) from 27.2 ± 4.21 nM (WT, n = 5) to
122.5 ± 16 nM (N46K n = 5; P = 0.0045; Fig. 2D).
Analysis of the N46 side-chain
We analysed the importance of N46 by conservatively sub-
stituting it for glutamine (Q), which retains the amide
side-chain. The glycine concentration–response curve
for N46Q (EC50 = 51 ± 4 μM; n = 5) was similar
to that for wild-type GlyRs (41 ± 3 μM; Fig. 3A).
However, concentration–response curves were displaced
to the right when the amide side-chain was replaced
with the negatively-charged carboxyl groups in aspartate
and glutamate, N46D (202 ± 51 μM; n = 8) and N46E
(272 ± 46 μM; n = 6; Fig. 3A), and even more so with
positively-charged lysine (N46K, 372 ± 4 μM).
We next investigated whether side-chain volume at
position 46 had any impact on GlyR function. By
substituting N46 for the smaller alanine, the glycine
concentration–response curve was displaced to a lesser
extent (A, EC50 182 ± 26 μM, n = 5) compared
with N46K. Replacing N46 with phenylalanine (F, EC50
2.26 ± 0.57 mM; n= 6), a large non-polar group, reduced
the sensitivity of the GlyR even more than for N46K.
Further increasing side-chain volume with tryptophan
(W;EC50 1.45± 0.10mM;n= 5), or changing charge using
the basic amino acid arginine (R; EC50 816 ± 130 μM;
n = 6) did not cause any greater displacement in
the concentration–response curve compared with N46F
(Fig. 3B). Smaller polar side-chain residues, lacking an
amide group, such as cysteine (C; EC50 330 ± 16 μM;
n= 6), serine (S; EC50 221± 22μM; n= 6) and threonine
(T; EC50 756± 133μM; n= 6), again significantly reduced
glycine potency compared with WT (Fig. 3C; Table 1).
These results demonstrate the critical importance of the
polar amide side-chain at position 46 for GlyR function.
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Figure 2. N46K reduces partial agonist potency and strychnine affinity
A, β-alanine concentration–response curves for WT and N46K GlyRs, normalised to the maximal glycine-activated
current for each cell. Glycine curves taken from Fig. 1C are shown as dashed lines. The β-alanine EC50s are:
90 ± 16 μM (WT; n = 7) and 552 ± 151 μM (N46K, n = 9) and relative maximum responses are WT = 92 ± 3%;
N46K = 90 ± 3%. B, taurine and GABA concentration–response curves for activating homomeric WT and N46K
GlyRs normalised to the maximum glycine-activated current for each cell. Dashed lines are the curves for glycine
activation of homomericWT and N46K receptors from Fig. 1C for comparison. C, inhibition concentration–response
curves for strychnine antagonism of an EC50 glycine response for WT (IC50: 12.2 ± 2.2 nM; n = 8) and N46K (IC50:
193.4 ± 52.3 nM; n = 10). D, Schild plot analysis of competitive antagonism by strychnine of EC50 responses to
glycine for WT and N46K GlyRs. Points represent mean dose-ratios (DRs) from all cells examined at each antagonist
concentration. The lines are fitted by linear regression and generated by the Schild equation with a constrained
slope = 1. The dotted lines depict the upper and lower 95% confidence intervals. The intercepts with the line at
DR ˗ 1 = 1, reveal the antagonist equilibrium constants.
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The structural role of N46
Using structural homology modelling, based on the
glutamate-activated Cl˗ channel (GluCl), and the atomic
resolution structures for the human α3 (Huang et al.
2015) and zebrafish α1 GlyR subunits (Du et al. 2015),
located the N46K mutation to within close proximity of
the orthosteric binding pocket; however, it was considered
unlikely to directly contribute to glycine binding (Fig. 4A).
Furthermore, it seems unlikely thatN46 fulfils anα-helical
capping action or stabilisation of a β loop, as the structural
projections placed this residue in the middle of a β loop
(Wan & Milner-White, 1999). However, the location of
N46 suggests it might interact with residues in binding
loop A of the neighbouring α1 subunit, or with other
residues in the same α1 subunit (e.g. in loop D; Fig. 4A).
Our receptor structures suggested that the side-chains
for loop A residues, N102 and E103, are directed away
from N46 implying that direct interactions are unlikely
(Fig. 4A), with N102 more likely to interact with its
own backbone (Pal & Sankararamakrishnan, 2008). To
investigate, N102 was exchanged for lysine (K; EC50
23 ± 2 mM; n = 7) or aspartate (D; EC50 0.42 ± 0.05 mM;
n = 4) resulting in 500- and 10-fold shifts, respectively,
in the glycine concentration–response curves compared
to WT (0.041 ± 0.003 mM; Fig. 4B). Charge reversal at
N46 (to K or D) and at N102 (to D or K) did not reverse
the displacement of the glycine curves to that observed
with WT (N46K-N102D: EC50 0.29 ± 0.07 mM; n = 7,
N46D-N102K; EC50 41 ± 9 mM; n = 6), suggesting it was
unlikely that N46 directly interacted with N102 (Fig. 4B).
In addition, mutating N46 and N102 to the same charged
residue resulted in non-functional glycine receptors.
Our structural models of GlyRα1 predicted that
asparagine 61, located within the same subunit as N46,
but on the juxtaposed loop D that houses a critical
glycine binding site residue R65 (Grudzinska et al. 2005;
Fig. 4A), was a prime candidate for interaction. Mutating
N61 to lysine had no significant effect on the glycine
concentration–response curve compared toWT.However,
mutating N61 to aspartate displaced the curve towards
lower glycine concentrations (Fig 4C and E: Table 2).
Interestingly, mutations that involved paired charge
reversals at N61 and N46 suggested these two residues
might interact; glycine potencywas either partially rescued
byN46K-N61Dor completely rescued by theN46D-N61K
pairing (Fig. 4D and E). The double mutant N46K-N61K
also rescued glycine potency back to WT levels, whilst
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Figure 3. Analysing the functional impact of residue 46 side-chain
A, glycine concentration–response curves for GlyRs with conservative or charged N46 mutations. B, glycine
concentration–response curves for mutations substituting N46 for alanine, phenylalanine, tryptophan or arginine.
C, glycine concentration–response curves for N46 mutations with smaller polar side-chain residues, lacking an
amide group, including cysteine, serine and threonine. See Table 1 for EC50 values.
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Table 1. Glycine potency at N46 mutant GlyRs
GlyRα1 EC50 (μm) Comparison with WT (P) Comparison with N46K (P) n
WT 41 ± 3 — — 20
N46K 372 ± 4 < 0.0001 — 19
N46Q 51 ± 4 0.0766 < 0.0001 5
N46D 202 ± 51 0.0253 0.0208 6
N46E 272 ± 46 0.0041 0.082 6
N46A 182 ± 26 0.0057 0.0019 5
N46F 2260 ± 570 0.0115 0.0212 6
N46W 1450 ± 100 0.0001 0.0004 5
N46R 816 ± 130 0.0019 0.0189 6
N46C 330 ± 16 < 0.0001 0.048 6
N46S 221 ± 22 0.0005 0.001 6
N46T 756 ± 133 0.003 0.0343 6
EC50 values for WT and N46 mutant GlyRs are shown. All values are means ± SEM for n cells. P values are shown for the comparisons
of the EC50 mean ± SEM values for mutant receptors with WT or N46K counterparts.
N46D-N61D significantly reduced glycine potency when
compared with curves for WT and also N46K GlyRs
(Fig. 4D and E; Table 2).
Allosteric modulation by Zn2+ and neurosteroids
GlyRs can be modulated by several allosteric ligands
(Lynch, 2004). Notably, Zn2+ binds to two discrete sites
on GlyRs (Miller et al. 2005b), causing potentiation and
inhibition at low and high micromolar concentrations,
respectively (Bloomenthal et al. 1994; Harvey et al. 1999;
Laube et al. 2000; Nevin et al. 2003; Miller et al. 2005a).
Co- or pre-applyingZn2+ with a glycine EC20 revealed that
N46K had no effect on Zn2+ potentiation of the glycine
current (Fig. 5A andB), whichwas also unaffected byA52S
(not shown). However, glycine-activated currents were
differentially inhibited by higher Zn2+ concentrations
(100μM), with homomericWT receptors showing greater
inhibition (80 ± 5% inhibition) compared to the N46K
mutant (25 ± 11 %; P < 0.05; Fig. 5B). By contrast,
A52S presented a similar Zn2+ inhibition profile to WT
(86 ± 1.6%; n = 5). Interestingly, another hyperekplexia
mutation GlyRα1E103K located in loop A (Chung et al.
2010), in a similar manner to N46K, reduced glycine
potency (EC50 910± 140μM;n= 7) and abolished 100μM
Zn2+ inhibition without affecting Zn2+potentiation (data
not shown).
Neurosteroids are endogenous molecules in the brain
that are capable of modulating GlyRs depending on the
receptor subunit composition (Belelli et al. 1999; Lynch,
2004; Fodor et al. 2006; Jin et al. 2009). Inhibition
of a glycine EC80 response by pregnenolone sulphate
(PS; 30 μM) was unaffected by either the N46K or
A52S mutations (Fig. 5C). However, potentiation by
10 μM tetrahydro-deoxycorticosterone (THDOC) of
glycine EC20 (189 ± 20%; Fig. 5D; n = 11) and glycine
EC50 (161 ± 19%; n = 5) responses for GlyR α1 were
significantly reduced by N46K (EC20: 139 ± 9%, Fig. 5D,
n= 8, EC50: 123 ± 11%; n= 7). However, potentiation of
the glycine EC20 (168 ± 16 %, n = 6) and EC50 (134 ± 10
%, n = 5) responses induced by 10 μM THDOC at the
α1A52S mutant was similar to WT. By comparison, GlyRs
containing the β subunit were relatively insensitive to
THDOC (Fig. 5D).
Picrotoxin sensitivity is reduced by N46K
Picrotoxin (PTX) inhibits homomeric GlyRs by blocking
the ion channel, but heteromers, containing theβ subunit,
are relatively less sensitive (Pribilla et al. 1992; Handford
et al. 1996; Fig. 5E and F). Picrotoxin (20 μM) inhibited
the EC50 peak glycine current for WT GlyRs by 61 ± 4
%, and for α1A52S mutant GlyR by 46 ± 3 % (n = 5).
By comparison, it caused less inhibition of equivalent
glycine currents at GlyR α1N46K (by 34 ± 6 %; Fig. 5E;
P < 0.05). The inhibition by 20 μM PTX of steady-state
glycine-activated currents was also greater forWT (81± 3
%) and A52S receptors (80 ± 4 %; n = 5) compared to
N46K (63 ± 7 %; Fig. 5F; P < 0.05).
Impact of N46K on single-channel currents
and agonist concentration jumps
To gain insight into how N46K affected the activation
of GlyRs, single-channel recording from cell-attached
patches was used. Single-channel currents were activated
by EC60 concentrations of glycine included in the patch
pipette solution (Fig. 6A). Using a patch potential of
+100 mV, a comparison between wild-type GlyRs and
N46K mutant revealed a small but significant (P = 0.017)
increase in channel current (WT, 6.35 ± 0.27 pA and
N46K, 7.95 ± 0.37 pA; n = 4–5), which overall equates
C© 2016 The Authors. The Journal of Physiology published by John Wiley & Sons Ltd on behalf of The Physiological Society
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Figure 4. Structure–function analyses of N46
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A, left panel, homology model of two adjacent GlyR α1 subunits. Right panel, expanded 30o tilted view of the
α1 subunit–subunit interface. The locations for N46 (grey) and K46 (purple) are shown, as well as two key glycine
binding residues: R65 (red, loop D) and E157 (blue, loop B); and relative side-chain orientations for N61 (red) and
R131 (green) at the complementary (˗) subunit interface, and N102/E103 (yellow) located on the principal side
(+) of the interface. The glycine binding loops are: A (yellow), B (blue), C (orange; removed for clarity), D (red),
E (green) and F (cyan). B, glycine concentration–response curves for reverse charge mutations at N102 and N46.
Single mutations of N102 to lysine or aspartate shifted the glycine curves to the right. Note substitutions of N46
and N102 with reverse charges (N46K-N102D: EC50 0.29 ± 0.07 mM; n = 7, N46D-N102K; EC50 41 ± 9 mM;
n = 6) did not restore WT GlyR sensitivity to glycine. Substitution of both N46 and N102 with the same charged
residues abolished sensitivity to glycine. C, the glycine curve for N61K overlays the WT curve, whilst N61D caused a
shift to the left. D, glycine concentration–response curves for paired N46 and N61 mutant GlyRs. Exchanging N46
and N61 with reverse charge mutants regained some (N46K-N61D) or all (N46D-N61K) of the sensitivity to glycine.
Substitution of N46 and N61 with the same charge, either recovered (N46K-N61K) or reduced (N46D-N61D) the
sensitivity to glycine compared to N46K GlyRs. E, homology models for N46 and N61 mutations in relation to the
surrounding residues in the same plane. Binding loops that are involved in the orthosteric binding site of pLGICs
are shown colour-coded: loop A (yellow), loop B (blue), loop C (orange; removed for clarity), loop D (red), loop E
(green) and loop F (cyan). DK – N46D, N61K; KD – N46K, N61D; KK – N46K, N61K; DD – N46D, N61D.
Table 2. Concentration–response curve data for N46 and N61 charge reversal mutants
GlyRα1 EC50 (μm) Hill slope Imax (pA) n
WT 41 ± 3 2.96 ± 0.40 3245 ± 570 20
N46K 372 ± 4∗ 1.89 ± 0.12∗ 2210 ± 367 19
N46D 202 ± 51∗ 1.20 ± 0.07∗ 1551 ± 126∗ 8
N61K 37 ± 7 1.39 ± 0.07∗ 2627 ± 716 7
N61D 6 ± 0.3∗ 2.27 ± 0.16 2893 ± 217 7
N46DN61K (DK) 22 ± 5∗ 1.03 ± 0.09∗ 964 ± 172∗ 6
N46KN61D (KD) 123 ± 18∗ 2.41 ± 0.15 3835 ± 931 7
N46KN61K (KK) 29 ± 7 0.98 ± 0.11∗ 1397 ± 206∗ 8
N46DN61D (DD) 10,863 ± 1,255∗ 1.29 ± 0.16∗ 6685 ± 1548 8
EC50, Hill slope and maximum current (Imax) parameters for WT GlyRs and selected mutants at N46 and N61 for n cells. All values are
means ± SEM. ∗Significant difference from the WT value; P < 0.05.
to a unitary conductance range of 65–80 pS. However,
since we are not controlling the HEK cell membrane
potential in cell-attached recording mode, this small
difference in single channel current could arise from small
changes to the membrane potential and thus the driving
force.
The channel open time distributions forWT and N46K
α1GlyRs were best described by two exponentials with
time constants τO1 and τO2 and areas AO1 and AO2
(Table 3). However, in a manner reminiscent of the hyper-
ekplexiamutantK276E (Lewis et al.1998),N46Kdisplayed
significant differences in the burst lengths and number of
openings per burst for glycine comparedwithWT (Fig. 6A
(expanded traces) and C and Table 3). The mean burst
duration was 3 times longer with 3 times as many
openings per burst for WT compared to N46K (Table 3;
P < 0.05).
Single-channel currents activated by EC60 concen-
trations of the partial agonist taurine were also investi-
gated. Taurine-activated channel current amplitudes were
similar betweenWTandN46KGlyRs (7.63± 0.4 pA (WT)
and 7.37 ± 0.5 pA (N46K); n = 5–6). Furthermore, the
taurine open time distributions were very similar for WT
and N46KGlyRs (Fig. 6B; Table 3), and unlike glycine, the
number of openings per burst and mean burst durations
evoked by taurine were not notably different betweenWT
and N46K GlyRs (Fig 6B and C; Table 3).
The changes detected for burst durations of
glycine-activated channels were investigated further by
using a fast application system to apply concentration
jumps of glycine or taurine to outside-out macropatches
containing either WT or N46K GlyRs (Fig 7). A 200 ms
application of EC60 glycine revealed a significantly faster
10–90% deactivation/desensitisation time for the N46K
mutant (26.1 ± 4.4 ms; n = 9) compared with WT
(98.2 ± 10.9 ms; P < 0.05; n = 10) with no change in
the activation kinetics (Fig. 7A and B).
Similarly, 2 ms applications of equipotent glycine
concentrations also revealed significantly faster current
deactivation for N46K (15.0 ± 2.3 ms; n = 6) compared
with WT receptors (60.4 ± 8.5 ms; P < 0.05; n = 6)
without affecting activation kinetics (WT; 1.10 ± 0.14 ms
and N46K; 0.92 ± 0.09 ms; Fig. 7A and B). Fast 200 ms
application of EC60 taurine presented a different profile to
glycine, with N46K exhibiting slower activation kinetics
with no apparent change in deactivation/desensitisation
C© 2016 The Authors. The Journal of Physiology published by John Wiley & Sons Ltd on behalf of The Physiological Society
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kinetics. However, the 2 ms taurine pulse showed faster
deactivation with N46K compared to WT (Fig. 7C
and D).
Overall, these data suggest that N46, located in close
proximity to theGlyR binding loops A andD, is important
for determining the duration of receptor activation by
glycine, predominantly by regulating the deactivation rate.
Discussion
Molecular mechanisms underlying startle disease
Dysfunctional glycinergic neurotransmission is the
major cause of human startle disease, with GlyRα1
gene mutations being the predominant cause. Various
mechanisms have been proposed to account for the
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Figure 5. Allosteric modulation at WT and N46K GlyRs
A, Zn2+ concentration modulation curves for the glycine EC20 response on WT and N46K GlyRα1. By co-applying
Zn2+ with EC20 glycine, there was no significant change in the potentiation or inhibition of the glycine-activated
peak current on WT compared with N46K GlyRα1. B, modulation of glycine EC20 responses following pre- and
co-application of Zn2+ (n = 5). C, effect of the neurosteroid, pregnenolone sulphate (PS; 30 μM; n = 5–9) on
peak glycine EC80 currents for α1, α1β, α1N46K and α1N46Kβ GlyRs. D, effect of the neurosteroid THDOC (10 μM;
n = 4–11) on peak glycine EC20 currents for α1, α1β, α1N46K and α1N46Kβ GlyRs. E, effect of picrotoxin (20 μM),
a GlyR channel blocker, on peak EC50 glycine-activated currents for α1, α1β, α1N46K and α1N46Kβ GlyRs (n = 4–6;
∗∗∗P < 0.0001). F, effect of picrotoxin (20 μM), a GlyR channel blocker, on steady-state EC50 glycine-activated
currents for α1, α1β, α1N46K and α1N46Kβ GlyRs (n = 4–6; ∗∗∗P < 0.0001).
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pathogenicity of GlyR missense mutations, including:
dysfunctional ligand binding and channel activation for
dominant mutations, to aberrant receptor trafficking and
assembly for recessive mutations (Davies et al. 2010).
However, we do not know how hyperekplexia mutations
at subunit–subunit interfaces disrupt GlyR function. Do
they displace the interfacial alignment between subunits
– a necessary pre-requisite for receptor activation – or do
they hinder agonist access towards, and its retention at, the
ligand binding site? The location of the N46K mutation
provided an opportunity to address these questions whilst
allowing insight into the activation mechanism for GlyRs
and the phenotypic variability between Glra1 hyper-
ekplexia mouse mutants.
Glycine receptor function and N46K
The Nmf11 missense mutation in Glra1, resulting in a
N46K substitution, exhibits recessive inheritance with a
phenotype including small body size, handling-induced
tremor, intense whole-body seizures and stiffness, an
impaired righting reflex, and compromised survival
by P21. However, transcription of Glra1 and GlyR
trafficking are unaffected by N46K as α1N46Kβ GlyRs
still cluster at inhibitory synapses (Traka et al. 2006).
Nevertheless, the Nmf11 phenotype has all the hallmarks
of severely compromised GlyR function normally
associated with the loss-of-function, oscillator and
cincinnatimutants.
0.05 mM Glycine GlyR α1 WT  
0.5 mM Glycine  GlyR α1N46K 
1 s
60 ms
250 ms
250 ms
60 ms
4 pA
1 s
4 pA
4 pA
4 pA
4 pA
4 pA
4 pA
4 pA
4 pA
4 pA
A
Open times (ms)
0.1 1 10 100
0
50
100
150
Open times (ms)
0.1 1 10 100
F
re
qu
en
cy
 d
en
si
ty
 (
sq
. r
t)
 
F
re
qu
en
cy
 d
en
si
ty
 (
sq
. r
t)
 
F
re
qu
en
cy
 d
en
si
ty
 (
sq
. r
t)
 
F
re
qu
en
cy
 d
en
si
ty
 (
sq
. r
t)
 
0
50
100
150
200
250
300
B
1 s
250 ms
0.4 mM Taurine  GlyR α1 WT 
0
100
200
300
400
500
600
700
Open times (ms)
0.1 1 10 100
1 s
250 ms
0.9 mM Taurine  GlyR α1N46K 
0
100
200
300
400
500
600
700
Open times (ms)
0.1 1 10 100
WT N46K WT N46K
0
1
2
3
4
5
6
7
8
M
ea
n 
N
o.
 o
f
O
pe
ni
ng
s\
bu
rs
t
Glycine Taurine
***
0
2
4
6
8
10
12
M
ea
n 
bu
rs
t d
ur
at
io
n 
(m
s)
WT N46K WT N46K
Glycine Taurine
***
C
Figure 6. Glycine and taurine single-channel currents for WT and N46K GlyRs
A, left, cell-attached recordings of single-channel currents evoked by EC60 concentrations of glycine on HEK cells
expressing homomeric WT and N46K GlyRs. Right, dwell time distributions for open states. Individual exponential
density functions required to fit components of the open time distributions are shown, including the overall fit.
B, left, cell-attached recordings of single-channel currents evoked by EC60 concentrations of taurine on WT and
N46K GlyRs. Right, open time distributions for taurine currents fitted with exponential density functions. C, the
mean number of openings per burst (left panel) and mean burst durations (right panel) were determined for WT
and N46K in the presence of glycine and taurine. See Table 3 for values (∗∗∗P < 0.0001).
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Table 3. GlyRα1 single-channel parameters
Agonist Glycine Taurine
GlyR WT N46K WT N46K
Open time τ1 (ms) 0.34 ± 0.048 0.25 ± 0.036 0.30 ± 0.043 0.28 ± 0.048
Area 1 (%) 44.39 ± 1.46 33.38 ± 1.53∗ 53.38 ± 3.31 51.91 ± 6.54
Open time τ2 (ms) 1.37 ± 0.26 1.56 ± 0.23 0.78 ± 0.074 1.06 ± 0.13
Area 2 (%) 56.8 ± 0.82 68.48 ± 1.45∗ 52.07 ± 3.21 51.99 ± 6.94
Shut time τC1 (ms) 0.12 ± 0.007 0.099 ± 0.012 0.11 ± 0.011 0.088 ± 0.003
Area C1 (%) 62.88 ± 8.65 47.44 ± 7.59 25.92 ± 2.63 20.62 ± 1.89
Shut time τC2 (ms) 0.44 ± 0.034 0.59 ± 0.25 1.76 ± 0.58 6.36 ± 3.95
Area C2 (%) 31.15 ± 4.62 16.36 ± 5.17 13.96 ± 4.23 19.14 ± 4.91
Mean open time (ms) 1.22 ± 0.188 1.2 ± 0.152 0.843 ± 0.234 0.674 ± 0.054
Mean burst duration (ms) 10.4 ± 1.3 3.5 ± 0.46∗ 1.02 ± 0.21 0.93 ± 0.11
Mean number of openings per burst 7.5 ± 0.4 2.6 ± 0.2∗ 1.5 ± 0.06 1.3 ± 0.04
Mean closed time within burst (ms) 0.296 ± 0.042 0.25 ± 0.034 0.215 ± 0.0291 0.197 ± 0.026
Exponential open (τO) and shut time (τC) constants and their associated areas. Numbers of bursts, and burst lengths are shown for
single-channel currents activated by GlyR agonists: glycine and taurine, for WT and N46K GlyRα1. Only time constants for the two
briefest shut states are shown to ensure shut times are measured bursts. All values are means ± SEM (n = 4–6; ∗Significant difference
from the WT value; P < 0.05 for 6000–12,000 transitions per patch).
The 9-fold increase in the glycine EC50 caused by N46K
would significantly reduce glycinergic inhibition, whilst
the spasmodic mutation (A52S) in GlyRα1 (Lane et al.
1987; Ryan et al. 1994; Plested et al. 2007) increased glycine
EC50 by only 2.5-fold, possibly explaining why spasmodic
shows exaggerated startle responses yet remains viable.
The glycine receptor is predominantly expressed as an
α2 homomer in embryonic and early postnatal periods
with a switch to α1β heteromers developing over time
such that the heteromer becomes the dominant receptor
population by P21 (Lynch, 2009). Both the α1N46K and
α1N46Kβ GlyRs exhibited reductions in glycine sensitivity
compared with the WT equivalents and it is conceivable
that the switch from α2 to α1N46Kβ GlyRs precipitates the
phenotype and premature death at P21. In addition to the
implications of increasing postsynaptic levels of α1N46K
GlyRs, causing dysfunction to glycinergic transmission,
the identification of presynaptic α1 homomeric GlyRs
(Turecek & Trussell, 2001) could also contribute to the
disease phenotype (Xiong et al. 2014). Presynaptic GlyRs
are thought to promote glycine release by depolarising
axon terminals due to Cl˗ efflux (Turecek & Trussell,
2001; Jeong et al. 2003). We would expect presynaptic
α1N46K GlyRs to impair such a depolarisation, reducing
glycine release, essentially resulting in disinhibition. This
effectwill further exacerbate the dysfunction to glycinergic
transmission leading to hyperekplexia.
Given the developmental profile of α1β heteromers
at P20 glycinergic synapses, we would expect glycine
to act as an inhibitory neurotransmitter such that
compromising receptor activity with the N46K mutation
should exacerbate neural circuit excitation.At earlier times
(P0–2), glycine fulfils an excitatory role as a consequenceof
high internal Cl˗ levels in neurons. However, it is doubtful
that the N46K mutation would be effective during this
earlier period given the relative paucity of α1β receptors
at this stage of development.
Overall, the correlationbetweenphenotype severity and
extent to which GlyR sensitivity to glycine is reduced,
under conditions where receptor trafficking and maximal
glycine currents are unaffected, may be an important
criterion for future genotype-phenotype studies of human
hyperekplexia.
N46K is unlikely to affect ion channel gating
The unalteredmaximal glycine-activated current for GlyR
α1N46K suggested that gating efficiency was possibly
unaffected. However, if agonist efficacy (E) is very high,
then a reduction in E would appear to displace the
curve with minimal reduction in the relative maximum
response. By using estimates of E for glycine activating
the fully liganded GlyR α1 (13–20; Lewis et al. 2003;
Lape et al. 2008), coupled to appropriate values for agonist
dissociation constants and a simple linear kinetic model,
a 9-fold shift in the glycine curve by reducing E alone
would cause the maximum response to fall by 60%.
Similarly, N46K caused 6-fold and 3-fold shifts in the
β-alanine and taurine curves, but it did not reduce the
maximal response when compared with glycine. From
our receptor model, (β-alanine E = 9 (Lewis et al. 2003);
taurine E= 3 (Lewis et al. 1998)), we would have expected
readily observable 55% to over 70% reductions in the
maximum responses, respectively, if channel gating was
C© 2016 The Authors. The Journal of Physiology published by John Wiley & Sons Ltd on behalf of The Physiological Society
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affected. Similar considerations of the pre-activation state
(Lape et al. 2008), which can be used to distinguish full
from partial agonists (Lape et al. 2008; Miller & Smart,
2010), also suggested that reduced formationof sucha state
is unlikely to account for the N46K phenotype, though
kinetic modelling (see below) indicated a potential effect
of N46K on one, triply liganded pre-activation state.
Effect of N46K on partial agonist and competitive
antagonist binding
Compared with the full agonist glycine, β-alanine, taurine
and GABA have lower affinities for and efficacies at
WT GlyRs, exhibiting depressed, right-shifted curves.
However,GlyRα1N46K did not depress these curves further,
and the shifts were notably smaller for theweaker agonists.
GABA and taurine may have different binding profiles
compared to glycine, potentially involving residues that
may be unimportant for glycine, and thus conceivably less
affected by N46K.
The prospect that N46K reduces glycine binding is
reinforced by the reduction in strychnine inhibition, an
effect that does not occur with A52S. Although strychnine
and glycine most likely bind to overlapping sites on
GlyRs (Grudzinska et al. 2005; Brams et al. 2011), our
receptor models indicate the lysine side-chain is too short
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Figure 7. Glycine currents deactivate
faster for N46K compared to WT GlyRs
A, glycine currents recorded from outside-out
macropatches evoked by applying EC60
concentrations of glycine (Gly) for either
200 ms (left panel) or 2 ms (right panel) on
HEK cells expressing WT GlyRs and N46K
GlyRs. Open tip responses are shown in
response to a pulse of 50% physiological salt
solution/H2O. Calibration bars are 50 ms and
200 pA. B, bar graphs quantify the 10–90%
glycine activation and
deactivation/desensitisation rates (n = 6–9;
∗∗∗P < 0.0001). C, recordings from
outside-out macropatches evoked by EC60
concentrations of taurine (Tau) for 200 ms (left
panel) or 2 ms (right panel) on HEK cells
expressing WT GlyRs (0.4 mM) and N46K
GlyRs (0.9 mM). Calibration bars are 50 ms
and 50 pA. D, bar graphs report the taurine
10–90% activation rates and also the
deactivation/ desensitisation rates (n = 6–9;
∗P < 0.05; ∗∗P < 0.005).
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to directly inhibit glycine binding, but could hinder (by
charge and/or volume) the binding of the much larger
strychninemolecule. N46K induced a comparable 15-fold
shift in the strychnine inhibition curve compared with the
9-fold shift for glycine.
N46 stabilises the receptor binding site
The importance of the amide side-chain at position 46
for maintaining the glycine sensitivity of WT GlyRs was
evident following substitution with residues that have
bulky hydrophobic (Trp, Phe) or charged (Lys, Arg, Glu,
Asp) side-chains. These all caused large displacements to
the glycine curve that did not occur with N46Q, which
retains the amidemoiety.The locationofN46near the sub-
unit interface and its apparent effect on glycine binding,
suggested it might interact with residues either located on
the adjacentα subunit or onβ loopswithin the sameα sub-
unit that are important for ligand binding.GlyR structures
suggest N46 points towards loop A, which is important for
binding in nicotinicAChRs (Cashin et al. 2007),GABAARs
(Padgett et al. 2007) and GlyRs (Miller et al. 2008),
though N46 was unlikely to interact directly with E103 or
N102 given their side-chain orientation. However, loop A
(β4 loop) could still be affected by N46K, particularly as
Zn2+ binding residues are nearby on β5 loop and N46K
reduced Zn2+ inhibition.
A parsimonious explanation for the N46 phenotype
may involve important ligand binding residues, on loop
D, which are upstream of N61 (Grudzinska et al. 2005).
Homology modelling, and recent GlyR structures (Du
et al. 2015; Huang et al. 2015) suggest N46 and N61
are juxtaposed (less than 3 A˚ apart) with the strychnine
binding residue, R131 in loop E, and loop A, all in the
same plane (Fig. 4A). The charge reversal experiments
involving N46 and N61 demonstrated that these two
asparagines could potentially interact, particularly given
the likelihood of de-protonated carboxyl groups in
their side-chains under physiological conditions. Possible
interactions between the two carboxamide side-chains
could include: electronic delocalisation, dipole–dipole
or charge–charge interactions. If these interactions are
disrupted, as indicated by the charged residue sub-
stitutions, this could alter the structural integrity of the
binding site located just above this plane, thus reducing
glycine binding.
Allosteric modulators
In regard to allosteric modulation, potentiation by Zn2+
was unaffected by either N46K or A52S, but Zn2+
inhibition was reduced by N46K. Both H107 and H109
on β5 loop (just outside loop A) constitute the Zn2+
inhibition site (Harvey et al. 1999; Nevin et al. 2003;
Miller et al. 2005a). SinceN46 faces loopA, across the sub-
unit interface, substitutionwith a positively charged lysine
could disrupt loop A, perturbing Zn2+ coordination and
compromising inhibition. This is supported by the results
with A52S, which is located further along the β strand
and thus away from loop A, and did not disrupt Zn2+
inhibition when compared with the WT. Interestingly,
E103K (loop A), a mutation that causes hyperekplexia in
humans (Chung et al. 2010), also reducedZn2+ inhibition.
By comparison with Zn2+, neurosteroid potentiation at
GlyRs was also reduced by N46K. This could contribute
towards lethality considering that thenon-lethalmutation,
A52S, exhibited a similar sensitivity to THDOC compared
to WT. The inhibition produced by picrotoxin, a GlyR
channel blocker, was also reduced by N46K, indicating
that ‘longer-range’ structural effects can result from
this mutation, which was less evident with the A52S
mutation.
Effect of N46K on single-channel currents and fast
concentration jumps
Single-channel data provided insight into how N46K
may reduce the potency of glycine. The major effect
appeared to involve reductions in themean burst duration
and mean number of openings per burst compared
with WT GlyRs. By contrast, the same parameters
were seemingly unaffected by taurine, reflecting the
smaller shift in the concentration curves by N46K. Using
glycine concentration jumps identified a significantly
faster deactivation of GlyRα1N46K compared to WT,
suggesting that N46K may destabilise the orthosteric
site allowing glycine to dissociate faster. Generally, the
deactivation kinetics for taurine were much faster than
for glycine and the differences between WT and N46K
were similar but less prominent. By comparison to
other hyperekplexia-inducing mutations, A52S caused a
reduction in the co-operativity between glycine binding
sites without affecting gating (Plested et al. 2007),
whilst the hyperekplexiamutation K276E hinders channel
opening causing shorter mean open times and reduced
whole-cell currents without affecting gating (Lewis
et al. 1998).
To account for the effects caused by N46K, we
constructed a three binding site model for the GlyR that
incorporated pre-activation states (Burzomato et al. 2004)
and was modified to include two desensitisation states
(Fig. 8A). To describe the changes to the glycine current
profiles and agonist concentration–response curves by
N46K required several empirical changes to rates and
constants. Primarily, the deactivation rates (and thus the
agonist dissociation constants (K1–3)) between states AR,
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A2R and A3R were increased (5-fold) together with
a reduction in the pre-activation constant, F3 (from
A3R to A3F, 9-fold; Table 4) to displace the glycine
concentration–response curve. To define the change in the
deactivation kinetics, the enhanced decay rates observed
for N46K were largely accounted for by increasing
the agonist unbinding rate (and thus Kf2) from the
pre-activation stateA3F toA2F by5-fold (Fig. 8; Table 4).
There are some similarities here with the changes induced
by A52S (Plested et al. 2007) including the reduction in F3
(9-fold) and increase in K (3-fold), which may reflect,
given the relative proximity of N46 and A52 in terms of
primary sequence, the impact this part of the extracellular
domain has on GlyR function.
A
B
25 ms
WT N46K WT N46K
200 ms 2 ms 
R AR A2R A3R
AF A2F A3F
AR* A2R* A3R*
A2D A3D
K1 K2 K3
F1 F2
E1 E2 E3
D1 D2
F3
Kf1 Kf2
Figure 8. Simulations of glycine currents at WT and N46K
GlyRα1
A, a kinetic model of the GlyR depicting 4 shut states (R, AR, A2R
and A3R), with 3 of these bound with up to 3 molecules of glycine
(A). Once agonist is bound, the AR, A2R and A3R states can undergo
pre-activation conformational transitions to states AF, A2F and A3F,
which are still shut states. These states can then undergo a gating
reaction to form AR∗, A2R∗ and A3R∗, which are open conducting
states. Two of these, A2R∗ and A3R∗ can enter into agonist-bound
desensitised states (A2D and A3D) when exposed to higher agonist
concentrations. Here, K is the agonist dissociation constant
(unbinding/binding rate = k ˗ 1/k1) taking account of statistical
factors for agonist binding and unbinding; Kf is the agonist
dissociation constant (kf-/kf+) for the pre-activation states; F is the
pre-activation conformation constant, = f1/f-1; E is the gating
constant, (= β/α); and D represents the desensitisation constant
(= δ1/δ-1; F, E and D = forward/backward rates). B, predicted
matched glycine-activated currents for WT (left, 50 μM) and N46K
GlyRs (right, 500 μM) using the model described in A. Glycine was
applied for either 2 or 200 ms. Note the faster deactivations for
N46K which largely result from increases in K and particularly in Kf
for the transition, A2F ↔ A3F. See text for details.
Table 4. Parameters used to generate the simulated currents in
Fig. 8
Rate constants WT N46K
K1 150 μM 727 μM
K2 120 μM 615 μM
K3 9.4 μM 47 μM
F1 0.73 0.6
F2 6 6.6
F3 23.4 2.99
Kf1 22 μM 56 μM
Kf2 22 μM 104 μM
E1 1.45 0.73
E2 14.75 9
E3 23.3 35
D1 5.7 8.5
D2 1.1 1.1
In conclusion, the N46K missense mutation markedly
reduced glycine sensitivity, resulting in a severe, lethal
startle phenotype. N46 most likely interacts with N61
to stabilise binding loops D and E near the orthosteric
site for glycine. By disrupting the structural integrity
of the glycine site (Fig. 9) N46K promotes agonist
unbinding from the orthosteric site, particularly from
the triple agonist molecule bound pre-activation state, to
cause faster GlyR deactivation. This mechanism reveals
a novel pathogenic effect for a hyperekplexia-inducing
mutation.
Glycine Binding Site
(R65, E157, Loop C)
Structural
(N46, N61, R131,Loop A)
A52
(A52S/spasmodic)
Figure 9. Structural model of the GlyR
Model showing a side-view of the GlyRα1 subunit interface
highlighting the important structural residues, N46, N61 and R131,
all residing in the same plane as loop A and positioned below the
orthosteric glycine binding site, involving residues: R65, E157 and
loop C.
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